Latest Conference Articles

Daridorexant Shows Efficacy as Insomnia Therapy With Evidence of No Withdrawal Effects

Daridorexant Shows Efficacy as Insomnia Therapy With Evidence of No Withdrawal Effects

June 21st 2021, 7:00pm

SLEEP

The Idorsia dual orexin receptor antagonist was accepted by the FDA for review in March 2021 and has shown efficacy in a number of SLEEP 2021 poster presentations.

FT218’s Effect on BMI Regardless of Stimulant Use: Asim Roy, MD

FT218’s Effect on BMI Regardless of Stimulant Use: Asim Roy, MD

June 18th 2021, 1:00pm

SLEEP

The medical director of the Ohio State Sleep Medicine Institute discussed the effect of FT218 in treating narcolepsy regardless of stimulant use, as well as its weight-related benefits it brings.

Future Areas of Progress for Sleep Disorder Care: Asim Roy, MD

Future Areas of Progress for Sleep Disorder Care: Asim Roy, MD

June 17th 2021, 1:00pm

SLEEP

The medical director of the Ohio State Sleep Medicine Institute detailed the progress made within the sleep disorder field in recent years and where it can turn to next.

NeuroVoices: Michael J. Thorpy, MD, on FT218, State of Current Sleep Care

NeuroVoices: Michael J. Thorpy, MD, on FT218, State of Current Sleep Care

June 16th 2021, 11:00am

SLEEP

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center detailed the overall state of sleep care and the advantages the investigational FT218 brings to the growing pipeline.

CBT-I Headlines AASM Guidelines for Chronic Insomnia

CBT-I Headlines AASM Guidelines for Chronic Insomnia

June 13th 2021, 4:00pm

SLEEP

The task force assessed 6 total interventions, all of which received conditional recommendations aside from cognitive behavioral therapy for insomnia, which was strongly recommended.

Solriamfetol Efficacious, Easily Titrated in Patients Initiating Treatment for Narcolepsy

Solriamfetol Efficacious, Easily Titrated in Patients Initiating Treatment for Narcolepsy

June 12th 2021, 7:00pm

SLEEP

Results from the START study of medication switching in narcolepsy were presented at the 2021 SLEEP Annual Meeting.

Telemedicine Produces Meaningful Migraine Improvement, Galcanezumab Shows No Wearing Effect, CGRPs All Significant Improve MMDs
Pitolisant Further Demonstrates Clinical Benefit on Excessive Daytime Sleepiness, Cataplexy

Pitolisant Further Demonstrates Clinical Benefit on Excessive Daytime Sleepiness, Cataplexy

June 11th 2021, 5:00pm

SLEEP

The FDA-approved agent demonstrated meaningful reduction in the frequency of cataplexy attacks in adults with narcolepsy, including patients with a high symptom burden.

FT218 Efficacious in Treating Narcolepsy Subtypes

FT218 Efficacious in Treating Narcolepsy Subtypes

June 10th 2021, 9:00pm

SLEEP

Data presented at SLEEP 2021 also showed the treatment was associated with significant weight loss and reduction in BMI compared to placebo.

Investigating INP104 for Migraine Treatment: Carrie Dougherty, MD, FAHS

Investigating INP104 for Migraine Treatment: Carrie Dougherty, MD, FAHS

June 10th 2021, 5:00pm

American Headache Society Annual Scientific Meeting

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed further research to be conducted with the nasal delivery of DHE.